DE60028367D1 - Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten - Google Patents
Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthaltenInfo
- Publication number
- DE60028367D1 DE60028367D1 DE60028367T DE60028367T DE60028367D1 DE 60028367 D1 DE60028367 D1 DE 60028367D1 DE 60028367 T DE60028367 T DE 60028367T DE 60028367 T DE60028367 T DE 60028367T DE 60028367 D1 DE60028367 D1 DE 60028367D1
- Authority
- DE
- Germany
- Prior art keywords
- antisense sequence
- seucidary
- oligonucleotide
- pharmaceutical compositions
- compositions containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9902921 | 1999-03-09 | ||
| FR9902921A FR2790757B1 (fr) | 1999-03-09 | 1999-03-09 | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. |
| PCT/FR2000/000586 WO2000053745A1 (fr) | 1999-03-09 | 2000-03-09 | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60028367D1 true DE60028367D1 (de) | 2006-07-06 |
| DE60028367T2 DE60028367T2 (de) | 2007-02-08 |
Family
ID=9542992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60028367T Expired - Lifetime DE60028367T2 (de) | 1999-03-09 | 2000-03-09 | Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7022832B2 (de) |
| EP (1) | EP1175489B1 (de) |
| JP (1) | JP2004500018A (de) |
| AT (1) | ATE328074T1 (de) |
| AU (1) | AU3295700A (de) |
| CA (1) | CA2363255A1 (de) |
| DE (1) | DE60028367T2 (de) |
| DK (1) | DK1175489T3 (de) |
| ES (1) | ES2265916T3 (de) |
| FR (1) | FR2790757B1 (de) |
| PT (1) | PT1175489E (de) |
| WO (1) | WO2000053745A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006477A1 (en) | 2001-07-12 | 2003-01-23 | University Of Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| US20090005332A1 (en) * | 2004-12-30 | 2009-01-01 | Hauser Todd M | Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides |
| EP1934348B1 (de) * | 2005-10-11 | 2018-05-02 | Ben-Gurion University Of The Negev Research And Development Authority | Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon |
| US20100144831A1 (en) * | 2006-09-27 | 2010-06-10 | Habib Fakhral | Blocking of gene expression in eukaryotic cells |
| US7645578B2 (en) * | 2006-10-31 | 2010-01-12 | Agilent Technologies, Inc. | Cleavage of RNA at redundant sites |
| ATE508191T1 (de) | 2006-11-01 | 2011-05-15 | Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase |
| WO2010045384A2 (en) * | 2008-10-15 | 2010-04-22 | Somagenics Inc. | Short hairpin rnas for inhibition of gene expression |
| CN102264898B (zh) | 2008-10-23 | 2013-10-16 | 国立大学法人东京大学 | 微小rna的功能抑制方法 |
| US8871730B2 (en) | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
| PT2933333T (pt) * | 2010-07-08 | 2018-04-24 | Bonac Corp | Molécula de ácido nucleico de cadeia simples para controlar a expressão génica |
| US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
| US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
| CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| EP2970965A2 (de) * | 2013-03-15 | 2016-01-20 | Pronai Therapeutics, Inc. | Dnai zur modulation von genen |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| SG10201805087VA (en) | 2013-12-27 | 2018-07-30 | Bonac Corp | Artificial match-type mirna for controlling gene expression and use therefor |
| AU2015368293B2 (en) | 2014-12-27 | 2021-07-22 | Bonac Corporation | Naturally occuring miRNA for controlling gene expression, and use of same |
| HK1244031A1 (en) | 2015-03-27 | 2018-07-27 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| CN116262919A (zh) | 2021-12-14 | 2023-06-16 | 成都凌泰氪生物技术有限公司 | 一种基于miRNA-2911的核酸分子 |
| WO2025096807A2 (en) * | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL172710B1 (pl) * | 1992-07-02 | 1997-11-28 | Hybridon Inc | Samostabilizujacy sie oligonukleotyd PL PL |
| GB2273932A (en) * | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
| FR2703053B1 (fr) * | 1993-03-26 | 1995-06-16 | Genset Sa | Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications . |
| US5631148A (en) * | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
-
1999
- 1999-03-09 FR FR9902921A patent/FR2790757B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-09 PT PT00910916T patent/PT1175489E/pt unknown
- 2000-03-09 WO PCT/FR2000/000586 patent/WO2000053745A1/fr not_active Ceased
- 2000-03-09 JP JP2000603366A patent/JP2004500018A/ja active Pending
- 2000-03-09 DE DE60028367T patent/DE60028367T2/de not_active Expired - Lifetime
- 2000-03-09 AU AU32957/00A patent/AU3295700A/en not_active Abandoned
- 2000-03-09 DK DK00910916T patent/DK1175489T3/da active
- 2000-03-09 EP EP00910916A patent/EP1175489B1/de not_active Expired - Lifetime
- 2000-03-09 ES ES00910916T patent/ES2265916T3/es not_active Expired - Lifetime
- 2000-03-09 AT AT00910916T patent/ATE328074T1/de not_active IP Right Cessation
- 2000-03-09 CA CA002363255A patent/CA2363255A1/fr not_active Abandoned
-
2001
- 2001-09-07 US US09/949,134 patent/US7022832B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2790757A1 (fr) | 2000-09-15 |
| ATE328074T1 (de) | 2006-06-15 |
| EP1175489B1 (de) | 2006-05-31 |
| JP2004500018A (ja) | 2004-01-08 |
| US20020156261A1 (en) | 2002-10-24 |
| CA2363255A1 (fr) | 2000-09-14 |
| AU3295700A (en) | 2000-09-28 |
| ES2265916T3 (es) | 2007-03-01 |
| EP1175489A1 (de) | 2002-01-30 |
| DK1175489T3 (da) | 2006-10-02 |
| WO2000053745A1 (fr) | 2000-09-14 |
| PT1175489E (pt) | 2006-10-31 |
| WO2000053745A9 (fr) | 2001-11-08 |
| DE60028367T2 (de) | 2007-02-08 |
| US7022832B2 (en) | 2006-04-04 |
| FR2790757B1 (fr) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60028367D1 (de) | Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten | |
| EP1798285B1 (de) | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens | |
| IL166546A (en) | Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene | |
| DE60325016D1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
| GR3024597T3 (en) | 7-deazapurine modified oligonucleotides | |
| WO2007143316A3 (en) | Compounds and methods for modulating expression of sglt2 | |
| DE69432315D1 (de) | ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT | |
| MX9700270A (es) | Composicion que contiene acidos nucleicos, preparacion y utilizacion. | |
| BR9914643A (pt) | Vetores adeno-associados para expressão dofator viii por células alvo | |
| WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
| DE69017983D1 (de) | Anti-sens Nukleotidsequenz, anti-RNS des alpha-TNFS, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel und pharmazeutische Präparate davon. | |
| WO2003101394A3 (en) | Defensins: use as antiviral agents | |
| EP1248633A4 (de) | Antisense-modulation der expression von glycogen-synthase kinase 3 beta | |
| EP2527442A3 (de) | Verbindungen und Verfahren zur Modulation von Genexpression | |
| EP2327784A3 (de) | Nukleinsäuren zur Hemmung der Expression de Hairless Proteins und Verfahren deren Benutzung | |
| WO2005039480A8 (en) | AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT | |
| DE60117572T2 (de) | Inhibitoren der Reversen Transkriptase von HIV aus tRNA | |
| WO1997004087A1 (de) | Ribozyme zur selektiven hemmung der expression von genen von mhc-allelen und diese enthaltende arzneimittel | |
| DK1537210T3 (da) | Decoy-oligonukleotid-inhibering af CD40-ekspression | |
| WO2004035759A3 (en) | Inhibitory oligonucleotides targeted to matrix metalloproteinase-9 | |
| YU87302A (sh) | Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |